J&J single-shot COVID-19 vaccine shows early promiseJ&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the Share XJ&J single-shot COVID-19 vaccine shows early promisehttps://pharmaphorum.com/news/early-data-backs-jjs-single-shot-coronavirus-vaccine-phase-3-results-due-soon/
Celltrion closes in on COVID-19 antibody market after trial successSouth Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first Share XCelltrion closes in on COVID-19 antibody market after trial successhttps://pharmaphorum.com/news/celltrion-closes-in-on-covid-19-antibody-market-after-trial-success/
Study says COVID-19 infection provides immunity, but people can transmit virusPrevious COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit Share XStudy says COVID-19 infection provides immunity, but people can transmit virushttps://pharmaphorum.com/news/study-says-covid-19-infection-provides-immunity-but-people-can-transmit-virus/
IO Biotech raises $155m to develop breakthrough cancer vaccineIO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) Share XIO Biotech raises $155m to develop breakthrough cancer vaccinehttps://pharmaphorum.com/news/io-biotech-raises-155m-to-develop-breakthrough-cancer-vaccine/
bluebird bio to split into oncology and gene therapy specialistsUS biotech bluebird bio has announced plans to split into two this year, with a separate oncology business Share Xbluebird bio to split into oncology and gene therapy specialistshttps://pharmaphorum.com/news/bluebird-bio-to-split-into-oncology-and-gene-therapy-specialists/
Chi-Med agrees R&D partnership with InmageneChina’s Chi-Med and Inmagene Biopharmaceuticals have agreed a strategic partnership to develop preclinical drug candidates for potential treatment Share XChi-Med agrees R&D partnership with Inmagenehttps://pharmaphorum.com/news/chi-med-agrees-rd-partnership-with-inmagene/
Sanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnSanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big Share XSanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnhttps://pharmaphorum.com/news/sanofi-buys-uks-kymab-and-inflammatory-disease-hopeful-for-1-45bn/
High hopes as Inventiva takes NASH contender into phase 3Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, Share XHigh hopes as Inventiva takes NASH contender into phase 3https://pharmaphorum.com/news/high-hopes-as-inventiva-takes-nash-contender-into-phase-3/
AI-designed serotonin tracker could help develop neurology drugsA serotonin sensor designed using Artificial Intelligence (AI) could help scientists study sleep and mental health and potentially Share XAI-designed serotonin tracker could help develop neurology drugshttps://pharmaphorum.com/news/us-scientists-use-ai-to-design/
